Home  |  Contact
Due to scheduled maintenance work, this service will not be available from Tuesday August 23rd 06:00 pm until Wednesday August 24th 08:00 am CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q16637: Variant p.Gly95Arg

Survival motor neuron protein
Gene: SMN2
Variant information

Variant position:  95
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Arginine (R) at position 95 (G95R, p.Gly95Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SMA3; reduces SMN binding to Sm proteins.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  95
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  294
The length of the canonical sequence.

Location on the sequence:   AKKNKSQKKNTAASLQQWKV  G DKCSAIWSEDGCIYPATIAS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIAS

                              AKKNKSQKKNATTALKQWKVGDKCSAVWSEDGCIYPATIAS

Mouse                         AKKNKSQKKNATTPLKQWKVGDKCSAVWSEDGCIYPATITS

Rat                           AKKNKNQKKNATAPLKQWKAGDKCSAVWSEDGCVYPATITS

Bovine                        A-KNKSQRKNTTSPSKQWKVGDNCCAIWSEDGCIYPATIAS

Cat                           AKKNKSQKKNTTAALKQWKVGDKCSAIWSEDGCVYPATIAS

Drosophila                    AGEISATGGATSPEPVSFKVGDYARATYV-DGVDYEGAVVS

Fission yeast                 --SIEAKGGVSDPDSR-------------------------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 294 Survival motor neuron protein
Domain 91 – 151 Tudor
Modified residue 85 – 85 Phosphothreonine; by PKA
Mutagenesis 92 – 92 W -> S. Impairs binding to substrate containing dimethylated arginine.
Mutagenesis 102 – 102 W -> LV. Impairs binding to substrate containing dimethylated arginine.
Mutagenesis 109 – 109 Y -> H. Impairs binding to substrate containing dimethylated arginine.


Literature citations

Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y.; Grimmler M.; Schwarzer V.; Schoenen F.; Fischer U.; Wirth B.;
Hum. Mutat. 25:64-71(2005)
Cited for: VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95; GLY-111; GLY-262; CYS-272 AND ILE-274; CHARACTERIZATION OF VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95 AND GLY-111;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.